PUBLICATIONS
Kaeser-Fröhlich A.: Are You Made for the Freelance Life? interaktiv, Volume 2, 2007.
Kaeser-Fröhlich A.: Glossary of Terms Used in Clinical Research. Caduceus, Winter 2003/2004.
Raßmann I., Thödtmann R., Mross M., Hüttmann A., Berdel W.E., Manegold C., Fiebig H.H., Kaeser-Fröhlich A., Burk K., Hanauske A.-R.: Phase I clinical and pharmacokinetic t rial of the podophyllotoxinderivative NK 611 administered as intravenous short infusion. Invest New Drugs 1999; 16 (4):319-324.
Braess J., Kern W., Unterhalt M., Kaufmann C.C., Ramsauer B., Schüßler M., Kaeser-Fröhlich A.,Hiddemann W., and Schleyer E.: Response to cytarabine ocfosfate (YNK01) in a patient with chroniclymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, andprednimustine/mitoxantrone . Ann Hematol 1996 Oct; 73 (4):201-4.
Raßmann I., Schroedel H., Schilling T., Zucchetti M., Kaeser -Fröhlich A., Rastetter J., Hanauske A -R.:Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21days every 35 days. Invest New Drugs 1996; 14(4):379-86.
Raßmann I., Schilling T., Mross K., Hüttmann A., Berdel W.E., Manegold C., Fiebig H.H., Kaeser -FröhlichA., Burk K., Rastetter J., Hanauske A. -R.: Clinical phase I evaluation of NK611 administered once every28 days. Ann Oncol 1996; 7 (Suppl. 1):101.
Pagani O., Zucchetti M., Sessa C., De Jong J., D’Incalci M., DeFusco M., Kaeser -Fröhlich A., HanauskeA-R., Cavalli F.: Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemother Pharmacol 1996; 38 (6):541-7.
Hanauske A.R., Wüster K.C., Lehmer A., Rotter M., Schneider P., Kaeser-Fröhlich A., Rastetter I., andDepenbrock H.: Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units fromfreshly explanted human tumours in vitro. Eur J Cancer 1995; Volume 31 (Suppl. 10):1677-81.
Rassman I., T. Schilling, H. Schroedel, Kaeser -Fröhlich A., Burk K., Rastetter R., and Hanauske A -R.:Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK 611 using an oral dailyadministration schedule. Eur J Cancer 1995; Volume 31 (Suppl. 6): S27.
Heußner P., Schleyer E., Amadori S., Ganser A., Guilhot F., Hanauske A.R., Heil, G., Hiddemann W.,Kolbe K., Selbach J., Stryckmans P., Willem ze R., Kaeser-Fröhlich A., Schüßler M., Burk K.; Freund M.: APhase I/II trial of YNK01, an oral ara -C derivative in patients with AML, MDS and low -grade malignantNHL. Onkologie 1994; 17 (Suppl. 2):61 (Abstr).
Hanauske A.-R., Wüster K.C., Depenbrock H., Peter R., Block T., Vogelsang H., Rotter M., Burk K.,Fröhlich A., Rastetter J.: Preclinical activity of NK -611, a new podophyllotoxin derivative, againstclonogenic tumor cells. Proc Amer Assoc Cancer Res 1994; 35:2388.
Schilling T., Mross K., Berdel W.E., Manegold C., Fiebig H.H., Hüttmann A., Kaeser-Fröhlich A.,Hanauske A.-R. for the Phase I Study Group of the AIO: Phase I clinical and pharmacokinetic trial of thepodophyllotoxin derivative NK611. Ann Oncol 1994;5 (Suppl. 5):193.
Zucchetti M., De Fusco M., Sessa C., Fröhlich A., Reichert S., D'Incalci M. : High-performance liquidchromatographic assay for the determination of the novel podophyllotoxin derivativedimethylaminoetoposide (NK611) in human plasma. J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):97-102.
Rogy S., Fröhlich A., Anderle K., Schoppmann A.: Factor VIII Inhibitors – Therapeutic Options. Die Ellipse,No. 19, June 1989.
Anderle K., Fröhlich A.: Review of studies with plasminogen concentrates and proposals for furthertherapeutic strategies with plasminogen concentrates. Haemostasis 1988; 18, Suppl.1:165-175.
The meeting was opened by President Bev at 10.05 a.m. who welcomed those present with a special welcome to our guests Jill and Roger Lockwood, Peter and Joy Molloy and Carol Lovegrove. A minutes silence was held in memory of our respected member the late Ed Thompson who recently passed away. Bev mentioned that she had a most enjoyable holiday and thanked Vice President Wilf for stepping in in h
PATRIMONIO CULTURAL INMATERIAL 1)Introducción: La intervención de la UNESCO para salvaguardar el Patrimonio Cultural inmaterial –PCI-, a través de políticas de preservación y ayuda a revitalizado la posición de los pueblos que conservaron a través del tiempo sus conocimientos, tradiciones ancestrales y a su vez ha legado conocimientos, en beneficio de la humanidad, basados en